Event Details

Verastem Inc at 12th International Mesothelioma Interest Group (iMig) Conference

Wednesday, October 22, 2014  through Friday, October 24, 2014 
Title
Verastem Inc at 12th International Mesothelioma Interest Group (iMig) Conference
Date / Time
October 22, 2014
Description

iMig Special Keynote Lecture: “Cancer Stem Cells as Target Pathways”
Presenter: Robert Weinberg, Ph.D., Whitehead Institute and Verastem scientific cofounder and chair of the Scientific Advisory Board

Presentation Title: “Determination of Biomarker response in a Phase II Window of Opportunity Study of Defactinib (VS-6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Subjects with Resectable MPM”
Presenter: Raphael Bueno, M.D., Chief, Division of Thoracic Surgery, Brigham & Women’s Hospital, Boston, MA

Presentation Title: “FAK Inhibitor VS-6063 (Defactinib) Targets Mesothelioma Cancer Stem Cells which are Enriched by Standard of Care Chemotherapy”
Presenter: Paul Baas, M.D., Ph. D., Department of Thoracic Oncology,The Netherlands Cancer Institute

Presentation Title: “The Cancer Stem Cell Inhibitors VS-6063 (Defactinib) and VS-5584 Exhibit Synergistic Anticancer Activity in Preclinical Models of Mesothelioma”
Presenter: Mitchell Keegan, Ph.D., Vice President, Development, Verastem